logo
logo

Bighat Biosciences Completes Its Acquisition Of Frugi Biotechnology

Mar 28, 2022•over 3 years ago

Acquiring Company

BigHat Biosciences

Acquired Company

Frugi Biotechnology

San MateoBiotechnologyOther

Description

BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology. The terms of the transaction were not disclosed.

Company Information

Company

BigHat Biosciences

Location

1900 ALAMEDA DE LAS PULGAS

San Mateo, California, United States

About

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed